Search Results for "Cartrol"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for Cartrol. Results 1 to 3 of 3 total matches.
See also: carteolol
Carteolol and Penbutolol For Hypertension
The Medical Letter on Drugs and Therapeutics • Jul 28, 1989 (Issue 797)
FOR
ONLINE USERS
CARTEOLOL AND PENBUTOLOL FOR HYPERTENSION
Carteolol (Cartrol - Abbott) and penbutolol ...
Carteolol (Cartrol - Abbott) and penbutolol (Levatol - Reed & Carnrick), two oral beta-adrenergic blocking drugs, were recently approved by the US Food and Drug Administration for once-daily treatment of systemic hypertension. Both drugs are non-selective beta-blockers with mild partial agonist activity. Beta-blockers currently available in the USA for treatment of hypertension are listed in the table on the next page.
Betaxolol for Hypertension
The Medical Letter on Drugs and Therapeutics • Jun 29, 1990 (Issue 821)
Carteolol − Cartrol (Abbott) 2.5 mg once/day 19.06
Labetalol − Normodyne (Schering) nonselective beta ...
Betaxolol (Kerlone - Searle), an oral beta-adrenergic blocker, was recently approved by the US Food and Drug Administration for once-daily treatment of hypertension. The new drug is beta 1 (cardio)-selective with no intrinsic sympathomimetic (partial agonist) activity. It is also available in a topical formulation for treatment of glaucoma (Betoptic - Medical Letter, 28:45, 1986). Beta-blockers currently available in the USA for treatment of hypertension are listed in the table below.
Which Beta-Blocker?
The Medical Letter on Drugs and Therapeutics • Feb 05, 2001 (Issue 1097)
price 5-20 mg 36.30 yes no low Hypertension
Zebeta (Lederle) 37.80
Carteolol − Cartrol (Abbott) 2.5-10 ...
Some classes of drugs include so many agents that hospital formulary committees, managed care organizations and individual practitioners may find it difficult to choose among them. Fifteen beta-adrenergic receptor antagonists (beta-blockers) are now marketed for systemic use in the USA. One or more have been approved by the FDA for use in hypertension and eight other indications.